Insulet Corporation (PODD)

Overview News Price History Option Chain Why PODD Down? Discussions Forecast

Insulet Corporation stock is currently priced at $164.73, with a 24-hour trading volume of 581.51K. It has seen a -0.92% decreased in the last 24 hours and a -4.05% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $168.4 pivot point. If it approaches the $163.0 support level, significant changes may occur.

Insulet Corporation Stock (PODD) Financials Data

Insulet Corporation (PODD) Revenue 2024

PODD reported a revenue (TTM) of $1.70 billion for the quarter ending December 31, 2023, a +30.02% rise year-over-year.

Insulet Corporation (PODD) Net Income 2024

PODD net income (TTM) was $206.30 million for the quarter ending December 31, 2023, a +4,385% increase year-over-year.

Insulet Corporation (PODD) Cash Flow 2024

PODD recorded a free cash flow (TTM) of $36.50 million for the quarter ending December 31, 2023, a +195.30% increase year-over-year.

Insulet Corporation (PODD) Earnings per Share 2024

PODD earnings per share (TTM) was $2.91 for the quarter ending December 31, 2023, a +1,112% growth year-over-year.

Insulet Corporation Stock (PODD) Latest News

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device. It also customizes the Omnipod System technology platform for the delivery of drugs over a specified interval of time, at an administered volume. The company sells and markets its Omnipod System through a combination of direct sales representatives and independent distributors. Insulet Corporation was founded in 2000 and is headquartered in Billerica, Massachusetts.

Upgrade	Robert W. Baird: Neutral → Outperform	Dec-21-23
Upgrade	Morgan Stanley: Equal-Weight → Overweight	Dec-04-23
Upgrade	Jefferies: Hold → Buy	Oct-02-23
Upgrade	Citigroup: Neutral → Buy	Aug-21-23
Downgrade	Robert W. Baird: Outperform → Neutral	Aug-21-23
Resumed	Morgan Stanley: Equal-Weight	May-30-23
Initiated	Wolfe Research: Peer Perform	Jan-26-23
Upgrade	Piper Sandler: Neutral → Overweight	Nov-04-22
Initiated	Barclays: Equal Weight	Oct-18-22
Initiated	Jefferies: Hold	Oct-12-22
Downgrade	Citigroup: Buy → Neutral	Jul-11-22
Resumed	BofA Securities: Buy	Mar-02-22
Upgrade	BTIG Research: Neutral → Buy	Feb-03-22
Upgrade	UBS: Neutral → Buy	Feb-02-22
Upgrade	Oppenheimer: Perform → Outperform	Jan-31-22
Resumed	Cowen: Outperform	Jul-21-21
Initiated	Barclays: Overweight	May-25-21
Upgrade	SVB Leerink: Mkt Perform → Outperform	Apr-01-21
Upgrade	Canaccord Genuity: Hold → Buy	Mar-19-21
Downgrade	Piper Sandler: Overweight → Neutral	Jan-29-21
Downgrade	Citigroup: Buy → Neutral	Dec-16-20
Initiated	Wells Fargo: Overweight	Jul-28-20
Downgrade	SVB Leerink: Outperform → Mkt Perform	Apr-24-20
Initiated	BofA/Merrill: Neutral	Apr-03-20
Downgrade	Berenberg: Buy → Hold	Mar-31-20
Initiated	Citigroup: Buy	Mar-05-20
Initiated	CFRA: Sell	Dec-10-19
Initiated	Stifel: Hold	Oct-23-19
Downgrade	Canaccord Genuity: Buy → Hold	Oct-18-19
Downgrade	BTIG Research: Buy → Neutral	Oct-14-19
Downgrade	UBS: Buy → Neutral	Oct-04-19
Downgrade	Guggenheim: Buy → Neutral	Oct-03-19
Upgrade	JP Morgan: Neutral → Overweight	Aug-06-19
Downgrade	Northland Capital: Outperform → Market Perform	Jun-10-19
Upgrade	BTIG Research: Neutral → Buy	May-06-19
Initiated	Berenberg: Buy	Apr-20-18
Reiterated	Barclays: Overweight	Feb-22-18
Upgrade	Raymond James: Mkt Perform → Outperform	Jan-08-18
Upgrade	Canaccord Genuity: Hold → Buy	Nov-03-17
Initiated	Barclays: Overweight	Sep-15-17